# 22nd Century Group, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/22nd Century Group, Inc.).

## Overview

22nd Century Group, Inc. (NASDAQ: XXII) is a U.S.-based tobacco products company built around tobacco harm reduction and contract manufacturing. Its core differentiation is proprietary agricultural biotechnology that regulates nicotine biosynthesis in the tobacco plant, enabling reduced nicotine content (RNC) tobacco and cigarettes marketed under the VLN® brand. The company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette (December 2021), which supports its positioning in reduced-nicotine products. Alongside its own branded offerings, it operates a vertically integrated contract manufacturing operation (CMO) producing conventional cigarettes and branded filtered cigars for third parties, including export-oriented customers.

## Products & services

• VLN® reduced nicotine cigarettes (95% less nicotine)
• Reduced nicotine content (RNC) tobacco plant technology/IP
• Contract manufacturing (CMO) of conventional cigarettes
• Contract manufacturing of branded filtered cigars
• Cigarillo distribution (through distributors)
• Research cigarettes (e.g., Spectrum® orders)

- **Contract manufacturing (CMO) cigarettes** (55%) — Manufacturing of conventional cigarettes for third-party customers, including export volume and large contracted accounts.
- **Contract manufacturing (CMO) filtered cigars** (20%) — Production of branded filtered cigars for customers under manufacturing contracts with repricing and mix shifts affecting volumes.
- **VLN® reduced nicotine cigarettes** (15%) — Company-branded reduced nicotine combustible cigarettes supported by FDA MRTP authorization and harm-reduction positioning.
- **Cigarillo distribution** (5%) — Distribution-driven cigarillo sales that can be influenced by distributor stocking and sell-through dynamics.
- **Research cigarettes and other** (5%) — Non-recurring or project-based research cigarette orders (e.g., Spectrum®) and other ancillary tobacco-related revenue.

- VLN® reduced nicotine cigarettes (95% less nicotine)
- Reduced nicotine content (RNC) tobacco plant technology/IP
- Contract manufacturing (CMO) of conventional cigarettes
- Contract manufacturing of branded filtered cigars
- Cigarillo distribution (through distributors)
- Research cigarettes (e.g., Spectrum® orders)

## Customers

22nd Century’s customer base spans both B2B manufacturing clients and end-market tobacco consumers via its own brands. A meaningful portion of revenue is tied to contract manufacturing customers that buy conventional cigarettes and filtered cigars under negotiated supply agreements, including a largest CMO customer with contract updates effective January 1, 2025. The company also sells product to U.S. customers for export, which can increase volume but pressure realized pricing depending on mix. On the branded side, adult smokers seeking to reduce nicotine intake are the target end users for VLN® reduced nicotine cigarettes, with demand influenced by retail distribution and regulatory messaging. The company also sees occasional institutional/research demand for research cigarettes, which can create one-time revenue spikes.

- **Contract manufacturing (CMO) cigarette customers** (primary) — Buy manufactured conventional cigarettes under contracts; value reliable supply, pricing terms, and capacity, including export-oriented volume.
- **Contract manufacturing (CMO) filtered cigar customers** (secondary) — Outsource production of branded filtered cigars; purchase decisions driven by unit economics, contract repricing, and product mix.
- **Adult smokers (VLN® end consumers via retail)** (secondary) — Purchase VLN® reduced nicotine cigarettes for nicotine reduction; demand depends on retail availability and harm-reduction positioning (MRTP).
- **Distributors (cigarillo channel)** (emerging) — Place stocking orders and distribute cigarillo products; ordering patterns can be lumpy due to inventory build and sell-through cycles.
- **Research/institutional customers** (emerging) — Buy research cigarettes for studies and testing; tends to be episodic (e.g., one-time Spectrum® order).

- Large CMO cigarette customer(s) buying under multi-term supply contracts
- Additional CMO cigarette customers added in 2025 driving higher carton volume
- Filtered cigar brand owners outsourcing manufacturing to XXII facilities
- U.S. customer(s) purchasing cigarettes for export (volume-driven, mix-sensitive)
- Distributors placing cigarillo stocking orders and managing sell-through
- Adult smokers purchasing VLN® for reduced nicotine consumption choice
- Research/institutional buyers placing one-time research cigarette orders

## Geography

The company is headquartered in the United States and primarily serves U.S.-based customers across its contract manufacturing and branded tobacco activities. Reported volumes indicate that some cigarette production is sold to a U.S. customer for export, making results partially sensitive to export mix and related pricing. Manufacturing is vertically integrated, implying internal control over key production steps for both company-branded products and CMO output. Because the filings provided do not include an authoritative revenue-by-geography table, a quantified regional revenue split is not presented here. Geographic exposure matters mainly through U.S. tobacco regulation (FDA/MRTP), domestic retail/distribution execution for VLN®, and export-driven mix shifts within CMO volumes.

- United States is the primary operating and customer market
- Export-linked sales occur via U.S. customers purchasing for export
- Vertical integration concentrates operational execution in owned facilities
- U.S. regulatory environment (FDA/MRTP) is central to VLN® positioning
- Export mix can change realized pricing and reported revenue per carton

## Strategy

The company’s strategy centers on tobacco harm reduction through commercialization of VLN® reduced nicotine cigarettes supported by its FDA MRTP authorization and patented nicotine-biosynthesis technology. In parallel, management is using contract manufacturing to drive near-term volume and utilize production capacity, including adding CMO cigarette customers and renegotiating/ repricing contracts. Product mix management is a recurring theme, with the company indicating a shift toward higher-margin branded cigarettes and VLN® while repricing lower-margin categories such as filtered cigars. Cost control is also evident through reductions in operating expenses (e.g., lower legal/consulting and headcount-related costs), reflecting a focus on liquidity while scaling revenue.

- **Expand CMO customer base and optimize contract economics** (short-term) — CMO volumes are a key near-term revenue driver; pricing terms can materially affect reported revenue and margins.
- **Commercialize and build demand for VLN® reduced nicotine cigarettes** (medium-term) — VLN® is the differentiated harm-reduction offering supported by MRTP authorization and proprietary RNC technology.
- **Improve product mix and profitability through repricing and category focus** (medium-term) — Mix shifts and contract repricing can raise gross margin and reduce dependence on low-priced export volume.

- Scale VLN® reduced nicotine cigarettes leveraging FDA MRTP authorization
- Monetize patented RNC tobacco technology as a product differentiator
- Grow CMO cigarette volumes by adding customers and renewing contracts
- Reprice contracts and shift mix toward higher-margin branded cigarettes
- Manage operating costs to extend liquidity amid ongoing losses

## Risks

A central company-specific risk is dependence on a small number of contract manufacturing customers, where contract terms (including consideration payable and stepped pricing) can reduce reported revenue and compress margins even when volumes rise. Regulatory risk is structurally high given the FDA’s role in tobacco oversight; while MRTP authorization supports VLN®, changes in regulatory standards, marketing restrictions, or enforcement could impair commercialization. Liquidity risk is elevated because the company has a history of significant losses and negative operating cash flow, increasing reliance on external financing and potentially dilutive securities. Operational risks include manufacturing execution, quality control, and agricultural/leaf supply variability that can disrupt production or raise costs. Industry risks include excise tax changes, litigation exposure typical to tobacco, and demand elasticity that can shift volumes across cigarettes, cigars, and reduced-nicotine alternatives.

- **CMO contract economics and customer concentration risk** [high] — Revenue and margin are sensitive to renegotiated terms (e.g., stepped changes in consideration payable) and reliance on large CMO customers.
- **Liquidity and going-concern style funding risk** [critical] — The company disclosed significant losses, negative operating cash flow, and an accumulated deficit, increasing dependence on financing.
- **Intangible asset impairment risk (patents)** [medium] — The company recorded impairment of patents, indicating valuation sensitivity to commercialization prospects and future cash flows.

- Customer concentration in CMO contracts can drive volatile revenue/margins
- Contract terms (consideration payable) can reduce reported net revenue
- Regulatory changes could limit VLN® marketing despite MRTP authorization
- Sustained losses and negative operating cash flow increase liquidity risk
- Export mix may increase volume but pressure pricing and profitability
- Manufacturing/quality failures could trigger returns, penalties, or lost clients
- Tobacco litigation and excise tax changes can raise costs and reduce demand

## Accounting

Revenue recognition is a key analytical area because the company’s CMO arrangements include complex pricing features such as consideration payable to customers and stepped contractual changes, which can reduce reported net revenue and affect period-to-period comparability. Management also noted that under legacy contracts, similar pricing arrangements were recorded in cost of goods sold, meaning classification changes can shift gross margin even if underlying economics are similar. Certain customer contracts include over-time revenue recognition and revenue accruals, which introduces estimation risk and can pull revenue forward relative to shipment timing. The company’s results can be distorted by non-recurring orders (e.g., a one-time Spectrum® research cigarette order), requiring normalization when assessing run-rate performance. Investors should also monitor impairment judgments for patents and other intangibles, as changes in expected cash flows can lead to write-downs that impact operating results.

- **Revenue recognition for CMO contracts (including consideration payable)** — Affects net revenue, gross profit, and comparability vs legacy contracts
- **Over-time revenue recognition and contract revenue accruals** — Timing of revenue and receivables/contract assets
- **Impairment of patents and other intangibles** — Operating expenses and asset carrying values

- CMO revenue netting: consideration payable reduces reported net revenue
- Classification shifts: legacy terms previously recorded in COGS vs revenue
- Over-time revenue recognition and accruals for certain customer contracts
- Non-recurring research cigarette orders can inflate prior-period revenue
- Patent/intangible impairment judgments can create operating expense spikes
- Reverse stock splits affect per-share comparability across periods

---

*Last updated: 2026-08-11T04:46:16.765817+00:00*